CKPT Checkpoint Therapeutics, Inc: יחס שווי שוק לערך בספרים

Checkpoint Therapeutics is preparing to launch cosibelimab as a budget-friendly alternative for skin cancer therapy. The company is leveraging the growing checkpoint inhibitor market, although funding shortages and the risk of failed trials pose significant threats. The price-to-book ratio on GURU.Markets reflects the asset valuation trend, where the current figure stands at 22.30.

For Checkpoint Therapeutics (CKPT), this indicator compares market valuation with the actual value of net assets. The metric calculates the ratio between market capitalization and book value, determining the extent of the premium or discount relative to assets. The historical price-to-book (P/B) ratio visualizes the price dependency on asset quality. For a biotech firm with a vulnerable economic moat and FDA regulatory risks, such a premium is critical. A high reading here signals excessive investor optimism.